The route by which B12 is supplied can matter, but a useful comparison needs a defined regimen, population, outcome and time point. The OB12 trial demonstrates why a favorable early result should not be stretched into a claim about every route or every duration of treatment.
The comparison changed over time
OB12 randomized 283 adults aged at least 65 years with B12 deficiency to oral or intramuscular regimens. Its primary outcome concerned normalization of serum B12, not a general energy score. More than 90 percent in each group met the biochemical criterion at eight weeks, when oral treatment met the study's noninferiority criterion. At 52 weeks, noninferiority was not established; 229 participants completed that follow-up. Primary trial abstract.
Noninferiority has a specific statistical meaning: an intervention is assessed against a predefined margin for how much worse it could be while remaining acceptable for the question studied. Failing to establish it is not automatically proof of superiority for the other intervention. Nor can success at an earlier time point guarantee success later.
This matters when a short summary says oral and injected B12 work equally well. That sentence erases both the study's margin and its time-dependent result. A better summary describes the early biochemical comparison and retains the uncertainty at a year.
Route is not the only difference worth checking
A trial compares the regimens actually assigned. Frequency, adherence and continuation over time are parts of that comparison, even when a headline emphasizes route alone. Without reviewing the full methods, an appraisal should not claim to have isolated the biological effect of administration route from every other feature.
This article relies on the primary indexed abstract. It does not reconstruct dosing schedules or recommend one. A more detailed methodological appraisal would need the full report, including missing-data handling and the prespecified noninferiority analysis.
Absorption claims need their own evidence
The NIH fact sheet notes that evidence does not establish different absorption rates among supplemental B12 forms. That limited statement should not be rewritten as proof that all products, routes or patient circumstances are clinically equivalent. NIH vitamin B12 fact sheet.
Absorption, a serum threshold and symptom improvement are related but separate endpoints. A preparation could change a blood measurement without answering whether a person's fatigue had a B12-related cause. Equally, a preference for one route does not prove superior clinical efficacy.
Keep the catalog question separate
OB12 did not test Serum Research's unspecified cobalamin material. Matching a catalog concentration to part of a trial description would not establish equivalent identity, quality or performance. The B12 forms overview explains the unresolved identity issue.
The research conclusion is therefore conditional and useful: early biochemical performance and sustained performance are different questions, and route comparisons should preserve both. Prepared for Serum Research, a commercial supplier, this analysis does not independently validate its products or replace individualized clinical assessment.
Published by Serum Research. Sources checked 2026-10-01. How we review evidence · Send a correction.